clinical

Articles

SD-OCT is providing reproducible, high-quality, registered images to assess the treatment response in macular disease.

Managing diabetic eye disease eased with repeatable, high-quality imaging

Videos

John B. Miller, MD, discusses widefield swept-source OCTA and its use in monitoring biomarkers in diabetic retinopathy.

Utilizing Widefield SS-OCTA to evaluate diabetic retinopathy severity

Cheryl Guttman is a medical writer based in Deerfield, Ill.

Confronting issues unique to aging may lead to better outcomes.

Addressing diabetic eye disease in senior patients

W. Lloyd Clark, MD, discusses his presentation at ASRS 2021, "Impact of Nonperfusion and Leakage Areas on Diabetic Macular Edema/Vision-Threatening Complications in Nonproliferative Diabetic Retinopathy (NPDR)."

PANOROMA elucidates effects of nonperfusion, leakage areas on DME, complications in NPDR

Lynda Charters Enoch started her early “eye life” at the Schepens Eye Research Institute, Boston, which ultimately culminated in her current position as an Editor of 

During a presentation at the American Society of Retina Specialists 2021 annual meeting in San Antonio, W. Lloyd Clark, MD, presented results of the PANORAMA Study. The focus of the study, Clark said, was to identify the factors that increase the risk of complications in patients with nonproliferative diabetic retinopathy to provide information for making decisions on treatment choices.

PANORAMA study outlines variables to watch when managing NPDR

Jennifer Sun, MD, MPH, explores the question of whether ophthalmologists should be using anti-VEGF agents to treat patients with nonproliferative diabetic retinopathy (NPDR).

Should anti-VEGF agents be used to treat patients with NPDR?

Ophthalmologists face challenges of drug delivery for retinal diseases.

The state of retina therapeutics, dissected by international panel

Visual benefit is not seen during first 2 years of Protocol W study.

Periodic aflibercept injections are studied in NPDR treatment

Investigators uncovered evidence that CaMKII could prove to be a desirable therapeutic target for vision preservation in conditions that damage the axons and somas of retinal ganglion cells.

Study suggests gene therapy could prevent vision loss in patients with retinal disease or injury

Dual imaging may reduce costs, unnecessary referrals, telehealth study results show.